269 related articles for article (PubMed ID: 7986315)
1. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
Dallongeville J; Fruchart JC; Pfister P; Bard JM
J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group.
Dallongeville J; Fruchart JC; Pfister P; Bard JM
Am J Med; 1994 Jun; 96(6A):32S-36S. PubMed ID: 8017464
[TBL] [Abstract][Full Text] [Related]
3. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
[TBL] [Abstract][Full Text] [Related]
4. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
5. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.
Lye M; Valacio R; Reckless JP; Ghosh AK; Findlay IN; Ghosh MK; Passmore AP; Fulcher RA
Coron Artery Dis; 1998; 9(9):583-90. PubMed ID: 9861520
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.
Bard JM; Dallongeville J; Hagen E; Pfister P; Ose L; Fruchart JC; Duriez P
Metabolism; 1995 Nov; 44(11):1447-54. PubMed ID: 7476333
[TBL] [Abstract][Full Text] [Related]
7. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
Samuelsson O; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Alaupovic P
Am J Kidney Dis; 2002 Jan; 39(1):67-75. PubMed ID: 11774104
[TBL] [Abstract][Full Text] [Related]
8. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events.
Stojakovic T; de Campo A; Scharnagl H; Sourij H; Schmölzer I; Wascher TC; März W
Eur J Clin Invest; 2010 Mar; 40(3):187-94. PubMed ID: 20067513
[TBL] [Abstract][Full Text] [Related]
10. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
[TBL] [Abstract][Full Text] [Related]
12. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study.
O'Rourke B; Barbir M; Mitchell AG; Yacoub MH; Banner NR
Int J Cardiol; 2004 Apr; 94(2-3):235-40. PubMed ID: 15093987
[TBL] [Abstract][Full Text] [Related]
16. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.
Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P
Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
18. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
20. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
